-
公开(公告)号：WO2021178556A1
公开(公告)日：2021-09-10
申请号：PCT/US2021/020697
申请日：2021-03-03
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： YOUNG, Tara , DALY, Christopher , THURSTON, Gavin
IPC: C12N15/113
Abstract: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g, by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-α) mediated killing by contacting the cells or administering the agent that inhibits autophagy.
-
公开(公告)号：WO2017040738A1
公开(公告)日：2017-03-09
申请号：PCT/US2016/049823
申请日：2016-09-01
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： SIAO, Chia-Jen , LEE, Hoi-Ching , LI, Zhe , LAI, Ka-Man Venus , THURSTON, Gavin
IPC: A01K67/027 , C12N15/85
CPC classification number: A01K67/0275 , A01K67/0271 , A01K2207/12 , A01K2217/05 , A01K2217/052 , A01K2227/105 , A01K2267/0331 , A01K2267/0393 , C07K7/08 , C07K2319/50 , C07K2319/61 , C12N5/0606 , C12N2015/8572 , C12N2830/008 , C12N2830/36
Abstract: This disclosure provides a rodent model of prostate cancer. The rodents disclosed herein comprise a transgene that provides prostate-specific expression of an oncogenic protein (e.g, an SV40 tumor antigen) under the control of 5' and 3' regulatory regions of a mouse probasin gene. The rodents develop progressive forms of prostate tumor that resemble the development of human prostate cancer.
Abstract translation: 本公开提供了前列腺癌的啮齿动物模型。 本文公开的啮齿动物包含在小鼠probasin基因的5'和3'调节区的控制下提供致癌蛋白（例如，SV40肿瘤抗原）的前列腺特异性表达的转基因。 啮齿动物形成类似前列腺癌发展的前列腺肿瘤的进展形式。
-
公开(公告)号：WO2017007796A1
公开(公告)日：2017-01-12
申请号：PCT/US2016/041055
申请日：2016-07-06
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： ANDREEV, Julian , THAMBI, Nithya , DELFINO, Frank , MARTIN, Joel , THURSTON, Gavin , CYGNAR, Katherine , PAPADOPOULOS, Nicholas
CPC classification number: A61K47/48569 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6879 , A61K2039/507 , C07K14/4702 , C07K16/1203 , C07K16/18 , C07K16/22 , C07K16/28 , C07K16/2833 , C07K16/2866 , C07K16/2869 , C07K16/2896 , C07K16/30 , C07K16/32 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/76 , C07K2317/77 , C07K2319/00 , C07K2319/30 , C12N9/6454
Abstract: The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the disclosure, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure causes or facilitates the targeted killing of tumor cells.
Abstract translation: 本公开提供多特异性抗原结合分子及其用途。 多特异性抗原结合分子包含特异性结合靶分子的第一抗原结合结构域和特异性结合内在效应蛋白的第二抗原结合结构域。 在一些实施方案中，本公开的多特异性抗原结合分子可以是能够结合靶分子和内化效应蛋白的双特异性抗体。 在本公开的某些实施方案中，通过本公开的多特异性抗原结合分子同时结合靶分子和内化效应蛋白导致目标分子的活性比所述靶分子的结合更大程度地减弱 靶分子单独。 在本公开的其它实施方案中，靶分子是肿瘤相关抗原，并且本公开的多特异性抗原结合分子同时结合肿瘤相关抗原和内化效应蛋白导致或促进靶向杀伤肿瘤细胞 。
-
公开(公告)号：WO2015112800A1
公开(公告)日：2015-07-30
申请号：PCT/US2015/012589
申请日：2015-01-23
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： PAPADOPOULOS, Nicholas, J. , MURPHY, Andrew, J. , THURSTON, Gavin , IOFFE, Ella , BUROVA, Elena
IPC: C07K16/28
CPC classification number: A61N5/10 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/31 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death- 1 (PD-1 ) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T- cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.
Abstract translation: 本发明提供结合T细胞共抑制剂程序性死亡-1（PD-1）蛋白的抗体及其使用方法。 在本发明的各种实施方案中，抗体是与PD-1结合的完全人抗体。 在某些实施方案中，本发明提供多特异性抗原结合分子，其包含结合PD-1的第一结合特异性和结合自身免疫组织抗原的第二结合特异性，另一T细胞共抑制剂，Fc受体 ，或T细胞受体。 在一些实施方案中，本发明的抗体可用于抑制或中和PD-1活性，从而提供治疗诸如癌症或慢性病毒感染的疾病或病症的方法。 在其它实施方案中，抗体可用于增强或刺激PD-1活性，从而提供治疗例如自身免疫疾病或病症的方法。
-
公开(公告)号：WO2014004427A3
公开(公告)日：2014-01-03
申请号：PCT/US2013/047476
申请日：2013-06-25
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： DALY, Christopher , THURSTON, Gavin , PADADOPOULOS, Nicholas, J.
IPC: C07K16/28
Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.
-
Patent Agency Ranking
公开(公告)号：WO2023004287A1
公开(公告)日：2023-01-26
申请号：PCT/US2022/073845
申请日：2022-07-18
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： DADI-MEHMETAJ, Saida , MOHRS, Markus , THURSTON, Gavin
IPC: A61K35/768 , A61K39/395 , A61P35/00
Abstract: This disclosure relates to novel triple combination therapies of an oncolytic virus, a PD-1 pathway inhibitor, and a CTLA4 inhibitor for treating or inhibiting the growth of a tumor in a patient with cancer.
-
公开(公告)号：WO2022271722A1
公开(公告)日：2022-12-29
申请号：PCT/US2022/034373
申请日：2022-06-21
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： DELFINO, Frank , KELLY, Marcus , KIRSHNER, Jessica , NITTOLI, Thomas , THURSTON, Gavin
IPC: C07K16/28 , A61K47/64 , A61K39/00 , A61K2039/505 , A61K47/6803 , A61K47/6849 , C07K16/2863 , C07K2317/34 , C07K2317/72
Abstract: The present disclosure provides antibody-drug conjugates (ADCs) comprising antibodies that bind to the class III variant of EGFR (EGFRvIII) conjugated to tesirine, and methods of using the same. According to certain embodiments, the antibodies or antigen-binding fragments thereof, useful herein, bind human EGFRvIII with high affinity. The antibodies or antigen-binding fragments thereof, useful herein, may be fully human antibodies. The ADCs provided herein are useful for the treatment of various cancers.
-
公开(公告)号：WO2022173931A1
公开(公告)日：2022-08-18
申请号：PCT/US2022/015950
申请日：2022-02-10
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： MILLER, Elizabeth , LOWY, Israel , THURSTON, Gavin , MERAD, Miriam , MARRON, Thomas , SCHWARTZ, Myron
Abstract: The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as neoadjuvant therapy followed by surgical resection and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC), the lung cancer is non-small cell lung cancer (NSCLC), or the head and neck cancer is head and neck squamous cell carcinoma (HNSCC).
-
公开(公告)号：WO2021174113A1
公开(公告)日：2021-09-02
申请号：PCT/US2021/020074
申请日：2021-02-26
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： ANDREEV, Julian , PEREZ BAY, Andres , DALY, Christopher , DELFINO, Frank , HAN, Amy , NITTOLI, Thomas , OLSON, William , THURSTON, Gavin
Abstract: Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.
-
公开(公告)号：WO2018102682A1
公开(公告)日：2018-06-07
申请号：PCT/US2017/064215
申请日：2017-12-01
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： KELLY, Marcus , MA, Dangshe , OLSON, William , THURSTON, Gavin
Abstract: Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.
-
-
-
-
-
-
-
-
-
Search Results
37
records
(took 0.021 seconds)
